Global Daratumumab Market Size, Share & Trends Analysis Report By Indication (Multiple Myeloma, Light Chain (AL) Amyloidosis, Other Hematologic Malignancies), By Line of Therapy (First-Line/Newly Diagnosed, Second-Line, Third-Line & Beyond, Maintenance), By Formulation (Intravenous Infusion, Subcutaneous Injection), By Combination Regimen (Daratumumab + Lenalidomide + Dexamethasone, Daratumumab + Bortezomib + Dexamethasone, Daratumumab + Bortezomib + Melphalan + Prednisone, Daratumumab + Carfilzomib + Dexamethasone, Daratumumab Monotherapy), By End-User (Hospitals & Cancer Centers, Specialty Oncology Clinics, Ambulatory Infusion Centers, Home Healthcare), and By Region (North America, Europe, APAC, Middle East & Africa, LATAM) - Forecasts, 2026-2034.

Table of Contents

1. Introduction

1.1. Market Introduction
1.2. Research Methodology
1.3. Estimation Methodology
1.4. Daratumumab Treatment Ecosystem Overview
1.5. Market Classification & Scope
1.6. Geographic Scope
1.7. Study Years

2. Market Dynamics

2.1. Drivers: Rising Multiple Myeloma Incidence, Frontline Therapy Adoption, Subcutaneous Formulation Uptake
2.2. Restraints: High Treatment Costs, Patent Expiry & Biosimilar Competition, Reimbursement Challenges
2.3. Opportunities: Combination Immunotherapy Expansion, Emerging Market Penetration, New Indication Development

3. Market Segmentation (2025–2034)

3.1. By Indication
3.2. By Line of Therapy
3.3. By Formulation
3.4. By Combination Regimen
3.5. By End-User
3.6. By Region

4. Regional Overview

4.1. North America
4.2. Europe
4.3. Asia Pacific
4.4. Middle East & Africa
4.5. Latin America

5. Competitive Analysis

5.1. Market Share Analysis
5.2. Product Portfolio & Pipeline Benchmarking
5.3. Biosimilar & Competitive Positioning
5.4. Strategic Collaborations, Licensing & Lifecycle Management

6. Technology & Innovation Trends

6.1. Subcutaneous Drug Delivery Technologies
6.2. Minimal Residual Disease (MRD)-Guided Therapy
6.3. Combination Immunotherapy & Quadruplet Regimens
6.4. Home-Based Oncology Treatment Models

7. Regulatory Landscape

7.1. FDA Approvals & Label Expansions
7.2. EMA & Global Regulatory Frameworks
7.3. Reimbursement & Market Access Policies
7.4. Biosimilar Approval & Intellectual Property Landscape

8. Market Research Findings & Conclusion

9. Disclaimer